MANNKIND CORP

Explore MannKind’s biotech journey—insider sales, high P/E, negative book value, and a $1.6B cap—while spotlighting its diabetes therapy Afrezza and future growth potential.

Investors weigh MannKind Corp.’s CEO share sale, high P/E, and trading consolidation—what it means for biotech stock value and future prospects.

FDA approves MannKind’s FUROSCIX for children, boosting its inhaled‑therapeutic line and market outlook amid CEO share sale.

Explore MannKind Corp’s biotech stock—volatility, insider sales, high P/E and negative P/B— and what it signals for investors.

Explore MannKind Corporation’s biopharma journey—its $1.72B market cap, focus on diabetes, cancer, and autoimmune therapies, and recent stock trends.

Explore MannKind Corp’s biotech prospects, market volatility, and strategic challenges as it seeks to diversify beyond Afrezza and secure investor confidence.

MannKind Corporation, a significant player in the biopharmaceutical industry, is navigating market dynamics and investor expectations as it focuses on developing and commercializing innovative therapeutic products to address critical health issues.

MannKind Corp has secured FDA acceptance for its inhaled insulin product, Afrezza, to be marketed to pediatric patients, marking a significant expansion of the product’s approved indications and potentially unlocking new revenue streams.

MannKind Corporation, a biopharmaceutical company, is at a critical juncture as it navigates the volatile health care industry, with its financial metrics and strategic positioning under scrutiny amidst significant stock price fluctuations and inves…

MannKind Corp has made significant strides in recent weeks, announcing a partnership with United Therapeutics and acquiring scPharmaceuticals, moves that are expected to bolster its position in the biopharmaceutical industry.